Published Online: Friday, December 1, 2006

The FDA gave marketing approval for the first generic version of MetroGel-Vaginal (metronidazole vaginal gel), calling the action "an important step in the agency's effort to increase the availability of lower-cost generic medications." The new generic, a treatment for bacterial vaginosis caused by an overgrowth of bacteria in the vagina, will be manufactured by Fort Collins, Colo-based QLT USA Inc, under the FDA's 180-day exclusivity rule.

"This approval is another example of our agency's efforts to increase access to safe and effective generic versions of approved brand name drugs as soon as the law permits," said Gary J. Buehler, director of the FDA's Office of Generic Drugs. "Metronidazole vaginal gel is a widely used antibacterial preparation, and its generic version can bring significant savings to the millions of Americans with bacterial vaginosis."

Latest Articles
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
Latest Issues